x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Therapeutic Science and Strategy

In this podcast series, Joel Sandler, Principal, BioConsulting, Cancer Cell Therapy Lead, sits down with various guests to talk about important topics that impact the pharmaceutical, biotech, and medical device industries.

science life sciences

All Episodes

35:03

Patient Progress: Mental Health in Caregivers

Therapeutic Science and Strategy ·

2025/10/07

Caregivers are often the unsung heroes of healthcare: key decision‑makers, advocates, researchers, and emotional anchors. Yet, support for their own mental health is frequently absent. In this episode, Lumanity's Jenny Payne sits down with Ashlee Cramer and Ceinwen Giles to break misconceptions (“Caregivers are saints and happy to do it”) and discuss the real impact — from anxiety, depression, and burnout to post‑traumatic growth (PTG). We explore how caregiving can mean sacrificing careers, social

en

09:38

Key Oncology Takeaways from ESMO 2024

Therapeutic Science and Strategy ·

2024/10/16

During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including: The importance of the patient and including the patient voice in drug development The way that Artificial Intelligence (AI) could impact and innovate cancer care Insights on a selection of early-phase extensive-stage small-cell lung cancer

en

28:31

Embracing the Pediatric Voice from Childhood Through...

Therapeutic Science and Strategy ·

2024/09/30

In this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research

en

16:44

Communications Testing Research: Unlock the Power of...

Therapeutic Science and Strategy ·

2024/05/15

In our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change. Our discussion includes: The importance of evaluating concepts using the right criteria Generating maximum impact using clear and simple ads that cut through the noise Being vigilant that the insights being used are robust and precise - and

en

29:53

Supporting Rare Disease Communities

Therapeutic Science and Strategy ·

2024/02/28

In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made

en

26:12

Making Social Media Listening Insights Count: Live or...

Therapeutic Science and Strategy ·

2024/01/24

In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making. Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include: How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions How SML best complements traditional research and data The value of SML in

en

18:06

Ensuring the Responsible and Meaningful Use of...

Therapeutic Science and Strategy ·

2023/12/07

In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making. Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring

en

30:27

The Importance of RWE Strategy Planning

Therapeutic Science and Strategy ·

2023/11/02

There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. Listen to this podcast to learn: · Key considerations, steps, and recommendations in identifying appropriate data sources · Where

en

28:15

Launch Excellence Alchemy: Managing Strategic Risk

Therapeutic Science and Strategy ·

2023/06/05

Strategic risk is often overlooked within the pharmaceutical industry. There’s a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch

en

28:40

Launch Excellence Alchemy: Mindset, Leadership, and...

Therapeutic Science and Strategy ·

2023/05/09

We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from ‘leading from the front’, towards a model that champions interdependent leadership and shared accountability. In the second episode of our series on launch excellence, we explore how:

en

19:46

Possible Implications of the Inflation Reduction Act...

Therapeutic Science and Strategy ·

2023/05/02

In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022. This episode covers: An overview of the IRA in relation to healthcare The potential impacts for oncology patients, manufacturers, and oncologists The impact of the legislation outside of the U.S. Speakers: Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity Rob Rawlinson, Director, Oncology

en

28:44

Launch Excellence Alchemy: Who Cares Wins

Therapeutic Science and Strategy ·

2023/04/03

During the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?" But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful launch teams. In the first episode of our series on launch excellence, we explore the following: How

en

20:57

Discussion with the CEO and CMO of ImCheck

Therapeutic Science and Strategy ·

2022/11/16

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content. In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss: Company origins, focus, and fundraising performance to date Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity Performance of ICT01, Imcheck’s clinical-stage lead program targeting BTN3A in gamma-delta T-cells Positioning and

en

26:36

Tailored Treatment Algorithms, Liquid Biopsy, and...

Therapeutic Science and Strategy ·

2022/09/13

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fifth episode, Joel sits down with Brian Leyland-Jones, MB BS, PhD, CMO, National Foundation for Cancer Research and Peter Kuhn, PhD, Dean’s Professor of Biological Sciences, Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology, to explore: Historical perspective on personalized approaches to

en

32:58

A Look Beyond: Scientific, Clinical, and Commercial...

Therapeutic Science and Strategy ·

2022/07/11

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fourth episode, Joel sits down with Jeff Bockman, Executive Vice President and Head of Oncology at Lumanity, and Michael Curran, PhD, Associate Professor, Department of Immunology, The University of Texas, MD Anderson Cancer Center, to explore: • The effort to develop agents for the CPI resistant/refractory patients. Where do we biologically and clinically

en

25:11

Changing the Narrative: The Story of an Ultra-rare...

Therapeutic Science and Strategy ·

2022/05/31

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this third episode, Joel sits down with Michael 'Mitch' Petrick, anaplastic thyroid cancer patient, to explore: Mitch's background and his rare form of thyroid cancer His journey from initial diagnosis (which he made!) through to referral and treatment Some thoughts about the drug development process and system from the perspective of someone in need of new

en

22:47

CAR-T in Solid Tumors: A Cancer Progress Sneak Peek

Therapeutic Science and Strategy ·

2022/04/25

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this second episode, Joel sits down with Shivani Srivastava, PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center, to explore: Key challenges to addressing solid tumors with cell therapy Recent developments (technology, scientific understanding) that are lowering these barriers The ultimate promise offered by cell therapy for solid

en

18:40

Not So Rare: Win-wins in Ultra-orphan Diseases

Therapeutic Science and Strategy ·

2022/02/25

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this first episode, Joel sits down with Michael Parisi, CEO of Guidemark, and Michael Rice, Vice President, Head of Advanced Therapeutics, to explore: How uncovering NSCLC and SMA genetics led to record-speed options for patients with rare subtypes How the patient advocacy groups enabled translation How the provider infrastructure is evolving to meet the need for

en

18 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter